<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006062.pub2" GROUP_ID="ENDOC" ID="993605063011062129" MERGED_FROM="" MODIFIED="2008-11-05 12:01:14 +0100" MODIFIED_BY="Gudrun Paletta" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-11-05 12:01:14 +0100" MODIFIED_BY="Gudrun Paletta">
<TITLE>Weight reduction for primary prevention of stroke in adults with overweight or obesity</TITLE>
<CONTACT MODIFIED="2008-11-05 12:01:14 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="C30FDE5A82E26AA2016B340A33BEA8EB" ROLE="AUTHOR"><FIRST_NAME>Cintia</FIRST_NAME><LAST_NAME>Curioni</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>c_curioni@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Instituto de Medicina Social</DEPARTMENT><ORGANISATION>Universidade do Estado do Rio de Janeiro</ORGANISATION><ADDRESS_1>Rua São Francisco Xavier, 524 / 7º andar / bloco D - Maracanã</ADDRESS_1><CITY>Rio de Janeiro</CITY><ZIP>20559-900</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 21 2548-3616</PHONE_1><FAX_1>+55 21 2548-3616</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-05 12:01:14 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="C30FDE5A82E26AA2016B340A33BEA8EB" ROLE="AUTHOR"><FIRST_NAME>Cintia</FIRST_NAME><LAST_NAME>Curioni</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>c_curioni@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Instituto de Medicina Social</DEPARTMENT><ORGANISATION>Universidade do Estado do Rio de Janeiro</ORGANISATION><ADDRESS_1>Rua São Francisco Xavier, 524 / 7º andar / bloco D - Maracanã</ADDRESS_1><CITY>Rio de Janeiro</CITY><ZIP>20559-900</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 21 2548-3616</PHONE_1><FAX_1>+55 21 2548-3616</FAX_1></ADDRESS></PERSON><PERSON ID="C32530BC82E26AA2016B340AC66ECFA8" ROLE="AUTHOR"><FIRST_NAME>Charles</FIRST_NAME><LAST_NAME>André</LAST_NAME><POSITION>Adjunct Professor</POSITION><EMAIL_1>andrecmd@unisys.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Neurology</DEPARTMENT><ORGANISATION>Federal University of Rio de Janeiro</ORGANISATION><ADDRESS_1>Serviço de Neurologia, Hospital Universario Clementino Fraga Filho,</ADDRESS_1><ADDRESS_2>Av Brigadeiro Trompowsky, s/no  sala 10E36</ADDRESS_2><CITY>Rio de Janeiro</CITY><ZIP>22441-090</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 021 25902738</PHONE_1><FAX_1>+55 021 25902738</FAX_1></ADDRESS></PERSON><PERSON ID="C71AC8C982E26AA2016B340ACEB0B253" ROLE="AUTHOR"><FIRST_NAME>Renato</FIRST_NAME><LAST_NAME>Veras</LAST_NAME><POSITION>Adjunct Professor</POSITION><EMAIL_1>veras@uerj.br</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Social Medicine</DEPARTMENT><ORGANISATION>State University of Rio de Janeiro</ORGANISATION><ADDRESS_1>Rua Sao Francisco Xavier, 524, 100 Andar, Bloco F - Maracana</ADDRESS_1><CITY>Rio de Janeiro</CITY><ZIP>20550-800</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 021 25877236</PHONE_1><FAX_1>+55 021 22640120</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-05 11:50:56 +0100" MODIFIED_BY="Gudrun Paletta">
<UP_TO_DATE>
<DATE DAY="30" MONTH="4" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="4" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="24" MONTH="8" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="4" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-04 17:16:09 +0200" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Fundo de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Deutscher Akademischer Austausch Dienst (DAAD)</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-05 11:58:44 +0100" MODIFIED_BY="Gudrun Paletta">
<SUMMARY MODIFIED="2008-10-04 17:18:48 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-04 17:18:43 +0200" MODIFIED_BY="[Empty name]">Weight reduction for primary prevention of stroke in adults with overweight or obesity</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-04 17:18:48 +0200" MODIFIED_BY="[Empty name]">
<P>Rigorous scientific evidence linking overweight or obesity with increased risk for stroke is missing.</P>
<P>Overweight and obesity are important public health problems and are associated with many serious health conditions including stroke which is a leading cause of death and severe long-term disability. It appears logical that weight reduction in overweight or obese people should have positive health consequences lowering the number and consequences of strokes. Overweight is defined as a "body mass index" (BMI) between 25.0 and 29.9 kg/m<SUP>2</SUP>, if weight measured in kilogram is divided by height measured in meter, and obesity as a BMI equal or greater than 29.9 kg/m<SUP>2</SUP>.<BR/>Despite a thorough search of the available literature we were not able to identify any study of good quality investigating the relationship between weight reduction and the occurrence of strokes. If overweight or obese people want to reduce their risk profile by losing weight they need sound evidence for doing so since every intervention might have negative consequences as well, for example losing and regaining weight ("weight cycling") is associated with health hazards like cardiovascular diseases. There is an urgent need for adequate research (good randomised controlled clinical trials) hopefully providing better advice in the future.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-10-04 17:17:09 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Obesity is seen as a worldwide chronic disease with high prevalence that has been associated with increased morbidity from many conditions including stroke, which is the third leading cause of death in developed countries and a leading cause of severe long-term disability. The causal association between overweight or obesity and stroke is unclear and there is no definite study clarifying the role of obesity treatment in the prevention of a first stroke (primary prevention). Given the prevalence of stroke and the enormous health and economic cost of the disease, it is important to establish the possible impact of weight reduction <I>per se</I> on stroke incidence.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of weight reduction in people with overweight or obesity on stroke incidence. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-04 17:17:09 +0200" MODIFIED_BY="[Empty name]">
<P>MEDLINE, EMBASE, <I>The Cochrane Library</I>, LILACS, databases of ongoing trials and reference lists were used to identify relevant trials. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials comparing any intervention for weight reduction (single or combined) with placebo or no intervention in overweight or obese people.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>No trials were found in the literature for inclusion in this review.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>There are currently no results to be reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Obesity seems to be associated with an increased risk of stroke and it has been suggested that weight loss may lead to a reduction of stroke occurrence. However, this hypothesis is not based on strong scientific evidence resulting from randomised controlled clinical trials. This systematic review identified the urgent need for well-designed, adequately-powered, multi centre randomised controlled trials assessing the effects of weight reduction in persons with overweight or obesity on stroke occurrence.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-05 11:58:44 +0100" MODIFIED_BY="Gudrun Paletta">
<BACKGROUND MODIFIED="2008-11-05 11:53:57 +0100" MODIFIED_BY="Gudrun Paletta">
<CONDITION MODIFIED="2008-11-05 11:53:48 +0100" MODIFIED_BY="Gudrun Paletta">
<SUBSECTION>
<HEADING LEVEL="3">Obesity</HEADING>
<P>According to the World Health Organization (WHO), obesity is a multifactorial chronic disease with increasing frequency in many countries that can be characterized as an epidemic of major public health concern (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>). Obesity is the condition of excessive fat in the body and might have significant health consequences. It is the result of weight gain caused when more energy is consumed than expended. In simple terms, people are getting fatter worldwide. The WHO defines overweight as a body mass index (BMI) between 25 to 29.9 kg/m² and obesity as a BMI equal or greater than 30 kg/m². Severe or morbid obesity is defined as a BMI equal or greater than 40 kg/m² or greater than 35 kg/m² in the presence of co morbidities (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>). BMI does not measure body fat directly but is a mathematical formula highly correlated with body fat. The basis for this BMI classification scheme stems from observational and epidemiologic studies which relate BMI to risk of morbidity and mortality (<LINK REF="REF-Clinical-Gdlns-1998" TYPE="REFERENCE">Clinical Gdlns 1998</LINK>). Normal weight is classified as a BMI between 18.5 to 24.9 kg/m² and a BMI less than 18.5 kg/m² is considered underweight.</P>
<P>Others methods in addition to the measurement of BMI are valuable in identifying individuals at increased risk from obesity-related illness due to abdominal fat accumulation. Waist circumference and waist-to-hip circumference ratio (WHR) provide a useful estimation of the proportion of abdominal or upper-body fat (<LINK REF="REF-Bj_x00f6_rntorp-1984" TYPE="REFERENCE">Björntorp 1984</LINK>; <LINK REF="REF-Bj_x00f6_rntorp-1985" TYPE="REFERENCE">Björntorp 1985</LINK>; <LINK REF="REF-Kissebah-1985" TYPE="REFERENCE">Kissebah 1985</LINK>). A WHR greater than 1.0 in men and 0.85 in women indicates abdominal fat accumulation; a high-risk waist circumference is thought to be 88 cm or greater for women and 102 cm or greater for men (<LINK REF="REF-Clinical-Gdlns-1998" TYPE="REFERENCE">Clinical Gdlns 1998</LINK>). Overweight and obesity seems to be associated with higher morbidity from many conditions such as arterial hypertension, type 2 diabetes mellitus, coronary heart disease, stroke, gallbladder disease, osteoarthritis, sleep apnoea and other respiratory problems and some types of cancer (for example, endometrium, breast, prostate, colon) (<LINK REF="REF-Clinical-Gdlns-1998" TYPE="REFERENCE">Clinical Gdlns 1998</LINK>). The abdominal fat is assumed to better correlate with increased mortality and risk of disorders such as diabetes mellitus, hyperlipidaemia, hypertension and cardiovascular diseases (<LINK REF="REF-Donahue-1987" TYPE="REFERENCE">Donahue 1987</LINK>; <LINK REF="REF-Ducimetiere-1986" TYPE="REFERENCE">Ducimetiere 1986</LINK>; <LINK REF="REF-Lapidus-1984" TYPE="REFERENCE">Lapidus 1984</LINK>; <LINK REF="REF-Larsson-1984" TYPE="REFERENCE">Larsson 1984</LINK>; <LINK REF="REF-Ohlson-1985" TYPE="REFERENCE">Ohlson 1985</LINK>; <LINK REF="REF-Stokes-1985" TYPE="REFERENCE">Stokes 1985</LINK>).</P>
<P>Obesity is seen as a condition, which requires treatment. Treatment means, first of all, weight reduction. The general goals of weight loss and management are: (1) to reduce body weight; and (2) to maintain a lower body weight over the long term; or (3) at a minimum, to prevent further weight gain. There is strong evidence that weight loss (5% to 15% of the body weight) in obese individuals reduces risk factors associated with obesity (<LINK REF="REF-Clinical-Gdlns-1998" TYPE="REFERENCE">Clinical Gdlns 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Stroke</HEADING>
<P>Stroke is the third leading cause of death in developed countries after heart disease and cancer and a leading cause of serious, long-term disability. Also, most of the developing countries show an increasing trend in mortality from stroke (<LINK REF="REF-Balaguer-Vintro-2004" TYPE="REFERENCE">Balaguer Vintro 2004</LINK>). Worldwide, three million women and 2.5 million men die from stroke every year (<LINK REF="REF-WHO-2004" TYPE="REFERENCE">WHO 2004</LINK>).</P>
<P>Stroke comprises two major types, haemorrhagic and ischaemic. Approximately 15% to 20% of strokes are haemorrhagic, divided between subarachnoid haemorrhage and primary intracerebral haemorrhage. The majority of strokes (approximately 80%) are ischaemic. When the symptoms are rapidly reversed (that is, in less than 24 hours), this would be considered a transient ischaemic attack. Stroke, whether due to infarction or haemorrhage, is associated with a previous history of high blood pressure in 50% of patients (<LINK REF="REF-Britton-1986" TYPE="REFERENCE">Britton 1986</LINK>; <LINK REF="REF-Oppenheimer-1992" TYPE="REFERENCE">Oppenheimer 1992</LINK>).</P>
<P>The clinical diagnosis of stroke is relatively straightforward. The acute onset (along minutes to hours) of focal neurological deficits related to a specific vascular territory in the absence of another evident mechanism, such as trauma, should lead to the presumptive diagnosis. The clinical impression should usually be followed by a diagnostic workup including a reliable differentiation between cerebral infarction and haemorrhage using neuroimaging techniques and a search for specific causes, such as embolism or large artery atherothrombosis.</P>
<P>The most widely available diagnostic method for exclusion of alternative diagnoses and for discrimination between haemorrhagic and ischaemic lesions is computed tomography (CT). Its main advantages are widespread availability and good sensitivity for haemorrhage. However, CT is insensitive to very early ischaemic changes following acute cerebral infarction especially in cases with small or infratentorial lesions.</P>
<P>Magnetic resonance imaging (MRI) exhibits distinct advantages over CT. Its high sensitivity for the diagnosis of parenchymal and subarachnoid haemorrhage has also already been demonstrated. MRI is becoming increasingly available and its gradual substitution for CT can be anticipated along the next decades in many countries.</P>
<P>Because of the limited options for treating patients once a stroke has occurred, the recognition of risk factors and aggressive preventive efforts remain the best way to reduce the burden of stroke. Risk factors and risk markers for a first stroke are usually classified according to their potential for modification (non modifiable, modifiable, potentially modifiable) (<LINK REF="REF-Goldstein-2001" TYPE="REFERENCE">Goldstein 2001</LINK>). The non-modifiable risk factors include age, sex, race or ethnicity and family history. Although these factors are non-modifiable, they identify individuals at higher risk of stroke and those who may benefit from rigorous prevention or treatment of modifiable risk factors (<LINK REF="REF-Sacco-1997" TYPE="REFERENCE">Sacco 1997</LINK>). The second group - modifiable risk factors - includes arterial hypertension, smoking, diabetes, hyperlipidaemia, asymptomatic carotid stenosis, atrial fibrillation, and other cardiac diseases. The third group includes conditions for which the evidence is still being mounted, such as obesity, alcohol and drug abuse, physical inactivity, hyperhomocysteinaemia, pro-thrombotic states, oral contraceptive use and hormone replacement therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Stroke and obesity</HEADING>
<P>Stroke incidence is higher in obese individuals, especially those with hypertension, diabetes or hypercholesterolaemia, all favoured by obesity. Adequate control of known risk factors reduces stroke incidence. Although recommended to improve the treatment of these cardiovascular risk factors (<LINK REF="REF-De-Freitas-2001" TYPE="REFERENCE">De Freitas 2001</LINK>), the possible impact of weight reduction <I>per se</I> on stroke incidence and mortality has not been adequately explored.<BR/>Obesity is seen as a modifiable risk factor for cardiovascular diseases, especially ischaemic heart disease. The causal association between obesity and stroke is less clear. Obesity increases the risk for hypertension, diabetes and dyslipidaemia (<LINK REF="REF-Brown-2000" TYPE="REFERENCE">Brown 2000</LINK>; <LINK REF="REF-Dyer-1989" TYPE="REFERENCE">Dyer 1989</LINK>; <LINK REF="REF-Ford-1997" TYPE="REFERENCE">Ford 1997</LINK>; <LINK REF="REF-Larsson-1981" TYPE="REFERENCE">Larsson 1981</LINK>; <LINK REF="REF-Ohlson-1985" TYPE="REFERENCE">Ohlson 1985</LINK>). On the basis of these associations alone, obesity should be related to an increased risk of stroke. However, studies documenting the specific impact of obesity or overweight on stroke showed heterogeneous results. In women, an increasing body mass index correlated with an increased risk of ischaemic stroke (<LINK REF="REF-Goldstein-2001" TYPE="REFERENCE">Goldstein 2001</LINK>). Abdominal obesity in men and obesity and weight gain in women seem to be independent risk factors for stroke (<LINK REF="REF-Kurth-2002" TYPE="REFERENCE">Kurth 2002</LINK>; <LINK REF="REF-Rexrode-1997" TYPE="REFERENCE">Rexrode 1997</LINK>). Weight gain after 18 years was also positively related to ischaemic stroke (<LINK REF="REF-Suk-2003" TYPE="REFERENCE">Suk 2003</LINK>).<BR/>In the Honolulu Heart Program, a high BMI was associated with an increased risk for thrombo-embolic strokes among nonsmoking middle-aged men (<LINK REF="REF-Abott-1994" TYPE="REFERENCE">Abott 1994</LINK>). In the Framingham Heart Study, an association between weight and incidence of atherothrombotic strokes was found only in women (<LINK REF="REF-Hubert-1983" TYPE="REFERENCE">Hubert 1983</LINK>). The Nurses' Health Study showed that women with an increased BMI had a higher ischaemic stroke risk. The association disappeared, however, after adjustment for hypertension, diabetes mellitus and high cholesterol (<LINK REF="REF-Rexrode-1997" TYPE="REFERENCE">Rexrode 1997</LINK>).<BR/>A number of additional studies support the association between obesity and stroke (<LINK REF="REF-Benfante-1994" TYPE="REFERENCE">Benfante 1994</LINK>; <LINK REF="REF-Jood-2004" TYPE="REFERENCE">Jood 2004</LINK>; <LINK REF="REF-Kurth-2002" TYPE="REFERENCE">Kurth 2002</LINK>; <LINK REF="REF-Milionis-2003" TYPE="REFERENCE">Milionis 2003</LINK>; <LINK REF="REF-Song-2004" TYPE="REFERENCE">Song 2004</LINK>). Other authors, however, were unable to find any independent relationship (<LINK REF="REF-Folsom-1990" TYPE="REFERENCE">Folsom 1990</LINK>; <LINK REF="REF-Lapidus-1984" TYPE="REFERENCE">Lapidus 1984</LINK>; <LINK REF="REF-Larsson-1984" TYPE="REFERENCE">Larsson 1984</LINK>; <LINK REF="REF-Lindenstrom-1993" TYPE="REFERENCE">Lindenstrom 1993</LINK>; <LINK REF="REF-Nj_x00f8_lstad-1996" TYPE="REFERENCE">Njølstad 1996</LINK>; <LINK REF="REF-Stokes-1987" TYPE="REFERENCE">Stokes 1987</LINK>).</P>
<P/>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2008-11-05 11:53:57 +0100" MODIFIED_BY="Gudrun Paletta">
<SUBSECTION>
<HEADING LEVEL="3">Stroke Prevention</HEADING>
<P>Stroke is a life-changing event that affects not only the person who may be disabled, but the entire family and other caregivers as well. Effective prevention remains the best treatment for reducing the burden of stroke.<BR/>Primary prevention of stroke includes lifestyle modifications (increase of physical activity, smoking cessation, reduction of alcohol consumption in heavy drinkers) and measures to control blood pressure, cholesterol levels, diabetes mellitus and atrial fibrillation. Primary prevention is particularly important because more than 70% of strokes are first events (<LINK REF="REF-Goldstein-2006" TYPE="REFERENCE">Goldstein 2006</LINK>).<BR/>Secondary prevention should focus on reducing the risk of a new vascular event after stroke. Besides carotid surgery and antithrombotic drugs, when appropriate, an optimal management of modifiable risk factors for stroke decreases the risk of new vascular events (<LINK REF="REF-Leys-2002" TYPE="REFERENCE">Leys 2002</LINK>).<BR/>Because obesity is a contributing factor to other risk factors associated with stroke, promoting weight loss and the maintenance of a "healthy weight" is a high priority.Adverse effects of the interventionWeight loss interventions in overweight or obese people could be associated with weight cycling. This condition could be dangerous because weight cycling may have a number of harmful consequences, including both physiological and psychological hazards (<LINK REF="REF-Nat-Task-Force-1994" TYPE="REFERENCE">Nat Task Force 1994</LINK>). Several large population-based studies have shown weight cycling to be associated with increased mortality (<LINK REF="REF-Blair-1993" TYPE="REFERENCE">Blair 1993</LINK>; <LINK REF="REF-Folsom-1996" TYPE="REFERENCE">Folsom 1996</LINK>; <LINK REF="REF-Lissner-1991" TYPE="REFERENCE">Lissner 1991</LINK>). An increased risk of morbidity, especially cardiovascular disease may be associated with fluctuations in body weight (<LINK REF="REF-Ernsberger-1996" TYPE="REFERENCE">Ernsberger 1996</LINK>; <LINK REF="REF-Jeffery-1996" TYPE="REFERENCE">Jeffery 1996</LINK>). Therefore, additional studies are needed to investigate the long-term safety and effectiveness of approaches to weight loss.</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2008-10-04 17:21:13 +0200" MODIFIED_BY="[Empty name]">
<P>Weight reduction and weight maintenance, as part of a lifestyle modification program, remain the cornerstone of treatment in people with overweight or obesity. Weight reduction interventions include: dieting, exercise, psychological or behavioural interventions, pharmacotherapy to suppress appetite or to change metabolism, surgical or laparoscopic gastroplasty to reduce food consumption and alternative therapies (<LINK REF="REF-Clinical-Gdlns-1998" TYPE="REFERENCE">Clinical Gdlns 1998</LINK>). A weight loss of 5% to 15% of baseline weight, may be associated with significant improvements in lipid levels, glycaemic control, and blood pressure control (<LINK REF="REF-Douketis-2005" TYPE="REFERENCE">Douketis 2005</LINK>). These effects could have the potential to reduce for example the incidence of cardiovascular morbidity and mortality. In this manner, weight loss may help control diseases worsened by overweight or obesity and may also decrease the likelihood of developing these diseases.</P>
</THEORY>
<IMPORTANCE MODIFIED="2008-10-04 17:21:30 +0200" MODIFIED_BY="[Empty name]">
<P>There is no systematic review evaluating the role of obesity treatment in the prevention of a first stroke (primary prevention). It is unclear whether there is evidence scientifically rigorous enough to recommend weight reduction for preventing stroke.<BR/>Given the prevalence of stroke and the enormous health and economic costs of the disease, this systematic review tries to collate all available data from randomised controlled clinical trials of obesity or overweight treatment in the primary prevention of stroke.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of weight reduction for primary prevention of stroke in adults with overweight and obesity. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-05 11:58:44 +0100" MODIFIED_BY="Gudrun Paletta">
<SELECTION_CRITERIA MODIFIED="2008-10-04 17:24:36 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised controlled clinical trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies including adults (at least 18 years) diagnosed as overweight (body mass index (BMI) 25 to 29.9 kg/m²) or obese (BMI equal to or more than 30 kg/m²). Studies with pregnant women as sole participants will be excluded. The diagnostic criteria for stroke will not be considered as an inclusion or exclusion criterion, but eventual differences will be explored in a sensitivity analysis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Randomised controlled clinical trials comparing any intervention for weight reduction with placebo or no intervention. Any concomitant interventions to control other cardiovascular risk factors, such as medication, should be identical in both groups. Trials will be included only if follow-up in the randomisation phase continued for at least one year.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-04 17:24:36 +0200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-04 17:24:07 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>incidence of first stroke;</LI>
<LI>all -cause mortality;</LI>
<LI>health-related quality of life (ideally measured by a validated instrument).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-04 17:24:36 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>adverse effects (for example depressive symptoms);</LI>
<LI>costs;</LI>
<LI>sequelae of strokes (for example functioning);</LI>
<LI>incidence of recurrent strokes;</LI>
<LI>incidence of diverse stroke types (ischaemic, haemorrhagic and unknown cause);</LI>
<LI>other vascular endpoints (for example fatal stroke, coronary heart disease, vascular death).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Specific patient covariates which may influence the weight reduction effect of the intervention as well as mortality and morbidity</HEADING>
<UL>
<LI>compliance with treatment;</LI>
<LI>BMI categories;</LI>
<LI>degree of weight reduction;</LI>
<LI>co-morbidity at the time of inclusion in the trial (for example diabetes, hypertension);</LI>
<LI>co-medication at the time of inclusion in the trial;</LI>
<LI>smoking;</LI>
<LI>weight regain, weight cycling;</LI>
<LI>physical activity.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Timing of outcome assessment</HEADING>
<P>Outcomes will be assessed in the long term (at least 12 months of follow-up).</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-05 11:55:09 +0100" MODIFIED_BY="Gudrun Paletta">
<ELECTRONIC_SEARCHES MODIFIED="2008-11-05 11:55:05 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The following electronic databases were searched to identify relevant trials:</P>
<UL>
<LI>
<I>The Cochrane Library </I>(up to 2006, issue 2)</LI>
<LI>MEDLINE (up to April 2006);</LI>
<LI>EMBASE (up to April 2006);</LI>
<LI>LILACS (up to April 2006).</LI>
</UL>
<P>The following databases of ongoing trials were searched:</P>
<UL>
<LI>Current Controlled Trials (http://www.controlled-trials.com);</LI>
<LI>National Research Register (http://www.update-software.com/National/nrr-frame.html);</LI>
<LI>National Institutes of Health (http://clinicalstudies.info.nih.gov/).</LI>
</UL>
<P>The search strategy was used for MEDLINE and adapted to suit the other databases. For detailed search strategies please see under <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-05 11:55:09 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We also searched the reference lists of reviews to try to identify relevant trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-05 11:58:44 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY_SELECTION MODIFIED="2008-11-05 11:57:03 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Two authors (CC and CA) independently scanned the titles, abstracts and keywords of trials identified through the respective search strategies. The full text of the articles was evaluated for inclusion whenever there was a suggestion that they:</P>
<UL>
<LI>included patients with overweight or obesity;</LI>
<LI>addressed a weight-reducing intervention;</LI>
<LI>assessed one or more relevant clinical outcome.</LI>
</UL>
<P>Articles were rejected on initial screen if both authors could positively determine from the title and abstract that they do not meet the inclusion criteria. The full text of the article was also reviewed if there was any persisting doubt about its inclusion. Agreement between the two authors was expressed using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). Eventual disagreement was resolved by discussion between the authors and if necessary with a third researcher. Excluded studies, after evaluation of full text articles, and the reasons for exclusion would have been clearly reported in a specific table. An adapted QUOROM (quality of reporting of meta-analyses) flow-chart of study selection was planned to be attached (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-05 11:57:29 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Two authors (CC and CA) will independently extract data from each study using a data extraction form based on the one provided by the Cochrane Metabolic and Endocrine Disorders Review Group. Differences between authors' extraction results will be resolved by discussion, and where necessary, in consultation with a third author. The following information were planned to be extracted:</P>
<UL>
<LI>general information: published or unpublished, title, authors, source, contact address, country, language and year of publication, duplicate publications, sponsoring, and setting;</LI>
<LI>participants: sampling (random or convenience), exclusion criteria, total number and number in the compared groups, age, gender, initial body mass index (BMI), assessment of compliance, similarity of groups at baseline (including any co-morbidity), withdrawals or losses to follow-up (reasons or description), subgroups;</LI>
<LI>trial characteristics: design, duration, randomisation (and its method), allocation concealment (and its method), blinding (patients, people administering treatment, outcome assessors), and check of blinding;</LI>
<LI>interventions: types, duration, description (schedule, dose, route, timing);</LI>
<LI>outcomes: outcomes specified above, any other outcomes assessed, other events, length of follow-up, quality of reporting of outcomes;</LI>
<LI>results: For dichotomous outcomes (stroke and other morbidities), the number of participants experiencing the event and the total number of participants in each arm of the trial will be extracted. Data on the number of patients with each outcome event and allocated to each treatment group, irrespective of compliance or follow-up, will be sought to allow an intention-to-treat analysis.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-11-05 11:58:07 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We wanted to explore the influence of individual quality criteria in a sensitivity analysis.</P>
<P>Additionally, we planned to assess the methodological quality of reporting of each trial based largely on the quality criteria specified by Schulz and Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). In particular, the following factors will be studied:<BR/>(1) Minimisation of selection bias - a) was the randomisation procedure adequate? b) was the allocation concealment adequate?<BR/>(2) Minimisation of performance bias - were the patients and people administering the treatment blind to the intervention?<BR/>(3) Minimisation of attrition bias - a) were withdrawals and dropouts completely described? b) was analysis by intention-to-treat?<BR/>(4) Minimisation of detection bias - were outcome assessors blind to the intervention?</P>
<P>Based on these criteria, studies will be broadly subdivided into the following three categories (see: <I>Cochrane Handbook for Systematic Reviews of Interventions</I> - <LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>):<BR/>A - all quality criteria met: low risk of bias.<BR/>B - one or more of the quality criteria only partly met: moderate risk of bias.<BR/>C - one or more criteria not met: high risk of bias.<BR/>This classification will also be used as a basis of a sensitivity analysis.</P>
<P>Each trial would have been assessed independently by two authors (CC, CA). Interrater agreement will be calculated using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). In case of disagreement, a third researcher will be consulted and a judgement will be made based on consensus. Studies will not be excluded only on the basis of a low quality score.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-10-04 17:37:05 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous outcomes (stroke incidence), results will be expressed as risk ratios (RR) or odds ratios (OR) together with 95% confidence intervals (CI).<BR/>Data will be analysed with a fixed effect model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time-to-event data</HEADING>
<P>Time-to-event outcomes (for example time until death) will be expressed as hazard ratios (HR) with 95% CI.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2008-10-04 17:37:17 +0200" MODIFIED_BY="[Empty name]">
<P>Different units of analysis (for example OR and RR) will be subjected to a sensitivity analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-10-04 17:37:38 +0200" MODIFIED_BY="[Empty name]">
<P>When necessary, additional information will be sought by correspondence with the main authors of the studies. Evaluation of important numerical data such as screened, eligible and randomised patients as well as intention-to-treat and per-protocol population will be carefully performed. Drop-outs, misses to follow-up and withdrawn study participants will be investigated.</P>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with duplicate publications</HEADING>
<P>In the case of duplicate publications and companion papers of a primary study, we will try to maximise yield of information by simultaneous evaluation of all available data. In cases of doubt, the original publication (usually the oldest version) will obtain priority.</P>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-10-04 17:37:50 +0200" MODIFIED_BY="[Empty name]">
<P>In the event of substantial clinical or methodological or statistical heterogeneity, study results will not be combined in meta-analysis. Heterogeneity will be identified by visual inspection of the forest plots, by using a standard &#967;<SUP>2 - </SUP>test and a significance level of &#945; = 0.1, in view of the low power of such tests. Heterogeneity will also be examined with I<SUP>2</SUP>, where I<SUP>2</SUP> values of 50% and more indicate a substantial level of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). When heterogeneity is found, we will attempt to determine potential reasons for it by examining individual study characteristics and those of subgroups of the main body of evidence.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-10-04 17:38:02 +0200" MODIFIED_BY="[Empty name]">
<P>Funnel plots will be used in exploratory data analysis to assess for the potential existence of small study bias. There are a number of explanations for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to study size, poor methodological design of small studies (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>) and publication bias. Thus, this exploratory data tool may be misleading (<LINK REF="REF-Tang-2000" TYPE="REFERENCE">Tang 2000</LINK>, <LINK REF="REF-Thornton-2000" TYPE="REFERENCE">Thornton 2000</LINK>) and we will not place undue emphasis on this tool.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-10-04 17:38:17 +0200" MODIFIED_BY="[Empty name]">
<P>Data will be summarised statistically if they are available, sufficiently similar and of sufficient quality. Statistical analysis will be performed according to the statistical guidelines referenced in the newest version of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). Pooled results will be analysed using primarily a random effects model. Meta-regression will be performed using Stata/SE (version 7, Stata Corporation, Texas U.S.A.) to determine whether various study-level characteristics (for example follow-up interval, duration of the intervention, total attrition, year of publication) affect the between-group change in primary outcomes. We will examine interaction terms for all models.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-11-05 11:58:36 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We planned to perform the following subgroup analyses in order to explore effect size differences, if there is a significant result for one of the main outcome measures:</P>
<UL>
<LI>population characteristics: age, gender and co-morbidity (presence of other risk factors);</LI>
<LI>intervention characteristics: type of intervention, length of follow-up and degree of weight reduction.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-11-05 11:58:44 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We planned to perform sensitivity analyses in order to explore the influence of the following factors on effect size:</P>
<UL>
<LI>repeating the analysis taking account of study quality, as specified above;</LI>
<LI>repeating the analysis excluding unpublished studies;</LI>
<LI>repeating the analysis excluding very long or very large studies to establish how much they dominate the results;</LI>
<LI>repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country.</LI>
</UL>
<P>The robustness of the results will also be tested by repeating the analysis using different measures of effects size (risk difference, odds ratio etc.) and different statistical models (fixed and random effects models).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-04 17:41:58 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-10-04 17:41:58 +0200" MODIFIED_BY="[Empty name]">
<P>No studies were found (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details of the amended QUOROM (quality of reporting of meta-analyses) statement).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Not applicable.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-04 17:40:39 +0200" MODIFIED_BY="[Empty name]">
<P>In order to find all possible studies, a search strategy was developed with a balance between comprehensiveness and precision. After checking the results of the search, no trials were eligible for inclusion. In the attempt to find studies, the search strategy was adapted. Again, no trials were found. Two additional searches were done, however, no studies could be included (for a detailed search strategy see under <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).<BR/>As described in the protocol, we attempted to find high level information evidence, looking for randomised controlled clinical trials. Thereafter, we tried to identify prospective cohort studies. A search strategy was developed to identify this type of observational study (for details see under <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). Unfortunately, we could not detect any prospective cohort study investigating the effects of weight loss or reduction on strokes in adults.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>We were not able to find suitable trials to assess the effects of weight reduction in people with overweight or obesity on stroke incidence. Therefore, at present we do not have reliable evidence to comment on the observed association between body weight and risk for stroke. Weight loss interventions, such as long-term pharmacotherapy, have to be justified by rigorous scientific evidence. Pathophysiological reasoning alone does not seem to be sufficient to draw inferences from association studies like cohort or case-control studies. Adequate long-term randomised trials are urgently needed to provide a better basis for rational decision making in this important public health area. <BR/>
</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There are insufficient data to make recommendations for practice about the effects of weight reduction in people with overweight or obesity on stroke incidence. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Overweight and obesity seem to be associated with an increased risk of stroke and it has been suggested that weight loss may lead to a reduction of stroke occurrence. However, this hypothesis is not based on strong scientific evidence from randomised controlled clinical trials. Research is urgently needed using a structured approach in the assessment of the long-term effect of weight loss on stroke incidence, taking into account both demographic and clinical variables. Well-designed, adequately-powered trials should incorporate long-term interventions, including a weight-loss and maintenance program, which ensure a sustainable weight loss, allowing the assessment of the effect of weigh loss on stroke occurrence. These studies should control for any concomitant risk factor, such as hypertension, diabetes or dyslipidaemia in order to establish the true effect of weight-loss. Due to the high drop-out and withdrawal rates in studies involving obese or overweight people, a great number of participants is necessary. For this purpose, multi centre collaboration, perhaps on an international scale, may be needed. A systematic review will hopefully be able to pool appropriate data in the future.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We are grateful to Bernd Richter for his valuable contribution and suggestions for this review</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-10-04 17:41:35 +0200" MODIFIED_BY="[Empty name]">
<P>CINTIA CURIONI: Drafted the protocol and review, searched for trials, obtained copies of trials, selection of studies, data extraction, assistance with statistics, data analysis and data presentation.</P>
<P>CHARLES ANDRE: Drafted the protocol and review, searched for trials, selection of studies, data extraction, data analysis and data presentation.</P>
<P>RENATO VERAS: Draft the protocol and review, selection of studies, data presentation.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-05 11:51:20 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-05 11:51:20 +0100" MODIFIED_BY="Gudrun Paletta">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-05 11:51:20 +0100" MODIFIED_BY="Gudrun Paletta">
<REFERENCE ID="REF-Abott-1994" NAME="Abott 1994" TYPE="JOURNAL_ARTICLE">
<AU>Abott RD, Behrens GR, Sharp DS, Rodriguez BL, Burchifiel CM, Ross W et al</AU>
<TI>Body mass index and thromboembolic stroke in nonsmoking men in older middle age: the Honolulu Heart Program</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>2370-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balaguer-Vintro-2004" NAME="Balaguer Vintro 2004" TYPE="JOURNAL_ARTICLE">
<AU>Balaguer Vintro I</AU>
<TI>Control and prevention of cardiovascular disease around the world</TI>
<SO>Revista Espanola de Cardiologia</SO>
<YR>2004</YR>
<VL>57</VL>
<PG>487-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benfante-1994" NAME="Benfante 1994" TYPE="JOURNAL_ARTICLE">
<AU>Benfante R, Yano K, Hwang LJ, Curb JD, Kagan A, Ross W</AU>
<TI>Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men: implications of shared risk</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>814-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bj_x00f6_rntorp-1984" NAME="Björntorp 1984" TYPE="JOURNAL_ARTICLE">
<AU>Björntorp P</AU>
<TI>Hazards in subgroups of human obesity</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>1984</YR>
<VL>14</VL>
<PG>239-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bj_x00f6_rntorp-1985" NAME="Björntorp 1985" TYPE="JOURNAL_ARTICLE">
<AU>Björntorp P</AU>
<TI>Obesity and the risk of cardiovascular disease</TI>
<SO>Annals of Clinical Research</SO>
<YR>1985</YR>
<VL>17</VL>
<PG>3-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blair-1993" NAME="Blair 1993" TYPE="JOURNAL_ARTICLE">
<AU>Blair SN, Shaten J, Brownell K, Collins G, Lissner L.</AU>
<TI>Body weight change, all-cause mortality, and cause-specific mortality in the Multiple Risk Factor Intervention Trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>7</VL>
<PG>749-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Britton-1986" NAME="Britton 1986" TYPE="JOURNAL_ARTICLE">
<AU>Britton M, Carlsson A, de Faire U</AU>
<TI>Blood pressure course in patients with acute stroke and matched controls</TI>
<SO>Stroke</SO>
<YR>1986</YR>
<VL>17</VL>
<PG>861-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2000" NAME="Brown 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E et al</AU>
<TI>Body mass index and prevalence of risk factors for cardiovascular disease</TI>
<SO>Obesity Research</SO>
<YR>2000</YR>
<VL>8</VL>
<PG>676-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clinical-Gdlns-1998" NAME="Clinical Gdlns 1998" TYPE="JOURNAL_ARTICLE">
<AU>National Institutes of Health. National Heart, Lung, and Blood Institute (NIHLBI)</AU>
<TI>Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report (Clinical Gdlns)</TI>
<SO>Obesity Research</SO>
<YR>1998</YR>
<VL>6</VL>
<PG>51S-209S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1960" NAME="Cohen 1960" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J</AU>
<TI>A coefficient of agreement for nominal scales</TI>
<SO>Educational and Psychological Measurement</SO>
<YR>1960</YR>
<VL>20</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Freitas-2001" NAME="De Freitas 2001" TYPE="JOURNAL_ARTICLE">
<AU>De Freitas GR, Bogousslavsky J</AU>
<TI>Primary stroke prevention</TI>
<SO>European Journal of Neurology</SO>
<YR>2001</YR>
<VL>8</VL>
<PG>1-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donahue-1987" NAME="Donahue 1987" TYPE="JOURNAL_ARTICLE">
<AU>Donahue RP, Abbott RD, Bloom E, Reed DM, Yano K</AU>
<TI>Central obesity and coronary heart disease in men</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>1</VL>
<PG>821-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Douketis-2005" NAME="Douketis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Douketis JD, Sharma AM</AU>
<TI>Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction</TI>
<SO>Seminars in Vascular Medicine</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>25-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ducimetiere-1986" NAME="Ducimetiere 1986" TYPE="JOURNAL_ARTICLE">
<AU>Ducimetiere P, Richard J, Cambien F</AU>
<TI>The pattern of subcutaneous fat distribution in middle-aged men and risk of coronary heart disease: The Paris Prospective Study</TI>
<SO>International Journal of Obesity</SO>
<YR>1986</YR>
<VL>10</VL>
<PG>229-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dyer-1989" NAME="Dyer 1989" TYPE="JOURNAL_ARTICLE">
<AU>Dyer AR, Elliott P</AU>
<TI>The INTERSALT study: relations of body mass index to blood pressure. INTERSALT Co-operative Research Group</TI>
<SO>Journal of Human Hypertension</SO>
<YR>1989</YR>
<VL>3</VL>
<PG>299-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ernsberger-1996" NAME="Ernsberger 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ernsberger P, Koletsky RJ, Baskin JS, Collins LA</AU>
<TI>Consequences of weight cycling in obese spontaneously hypertensive rats</TI>
<SO>American Journal of Physiology</SO>
<YR>1996</YR>
<VL>270</VL>
<PG>R864-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Folsom-1990" NAME="Folsom 1990" TYPE="JOURNAL_ARTICLE">
<AU>Folsom AR, Prineas RJ, Kaye SA, Munger RG</AU>
<TI>Incidence of hypertension and stroke in relation to body fat distribution and other risk factors in older women</TI>
<SO>Stroke</SO>
<YR>1990</YR>
<VL>21</VL>
<PG>701-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Folsom-1996" NAME="Folsom 1996" TYPE="JOURNAL_ARTICLE">
<AU>Folsom AR, French SA, Zheng W, Baxter JE, Jeffery RW</AU>
<TI>Weight variability and mortality: the Iowa Women's Health Study</TI>
<SO>International Journal of Obesity and related Metabolic Disorders</SO>
<YR>1996</YR>
<VL>20</VL>
<PG>704-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ford-1997" NAME="Ford 1997" TYPE="JOURNAL_ARTICLE">
<AU>Ford ES, Williamson DF, Liu S</AU>
<TI>Weight change and diabetes incidence: findings from a national cohort of US adults</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1997</YR>
<VL>146</VL>
<PG>214-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-2001" NAME="Goldstein 2001" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademones G</AU>
<TI>AHA Scientific Statement: primary prevention stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association</TI>
<SO>Stroke</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>280-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-2006" NAME="Goldstein 2006" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Brushnell CD et al</AU>
<TI>Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes. Research Interdisciplinary Working Group</TI>
<SO>Circulation</SO>
<YR>2006</YR>
<VL>113</VL>
<PG>e873-923</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2008-11-05 11:50:06 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Higgins 2005" TYPE="COCHRANE_REVIEW">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hubert-1983" NAME="Hubert 1983" TYPE="JOURNAL_ARTICLE">
<AU>Hubert HB, Feinleib M, McNamara PM, Castelli WP</AU>
<TI>Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study</TI>
<SO>Circulation</SO>
<YR>1983</YR>
<VL>67</VL>
<PG>968-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ et al</AU>
<TI>Assessing the Quality of Reports of Randomised Clinical Trials: Is Blinding Necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeffery-1996" NAME="Jeffery 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jeffery RW</AU>
<TI>Does weight cycling present a health risk?</TI>
<SO>American Journal of Clinical Nutrition</SO>
<VL>63</VL>
<PG>S452-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jood-2004" NAME="Jood 2004" TYPE="JOURNAL_ARTICLE">
<AU>Jood K, Jern C, Wilhelmsen L, Rosengren A</AU>
<TI>Body mass index in mid-life is associated with a first stroke in men: a prospective population study over 28 years</TI>
<SO>Stroke</SO>
<YR>2004</YR>
<VL>35</VL>
<PG>2764 -9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kissebah-1985" NAME="Kissebah 1985" TYPE="BOOK_SECTION">
<AU>Kissebah AH, Evans DJ, Peiris A, Wilson CR</AU>
<TI>Endrocrine characteristics in regional obesities:role of sex steroids</TI>
<SO>Metabolic Complications of Human Obesities</SO>
<YR>1985</YR>
<PG>115-30</PG>
<ED>Vague J, Björntorp P, Guy Grand B, Rebuffé-Scrive M, Vague P</ED>
<PB>Elsevier Science Publishers, Amsterdam</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurth-2002" NAME="Kurth 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR et al</AU>
<TI>Body mass index and the risk of stroke in men</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<PG>2557-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lapidus-1984" NAME="Lapidus 1984" TYPE="JOURNAL_ARTICLE">
<AU>Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L</AU>
<TI>Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden</TI>
<SO>BMJ</SO>
<YR>1984</YR>
<VL>289</VL>
<PG>1257-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Larsson-1981" NAME="Larsson 1981" TYPE="JOURNAL_ARTICLE">
<AU>Larsson B, Bjorntorp P, Tibblin G</AU>
<TI>The health consequences of moderate obesity</TI>
<SO>International Journal of Obesity</SO>
<YR>1981</YR>
<VL>5</VL>
<PG>97-116</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Larsson-1984" NAME="Larsson 1984" TYPE="JOURNAL_ARTICLE">
<AU>Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G</AU>
<TI>Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 years follow up of participants in the study of men born in 1913</TI>
<SO>BMJ</SO>
<YR>1984</YR>
<VL>288</VL>
<PG>1401-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leys-2002" NAME="Leys 2002" TYPE="JOURNAL_ARTICLE">
<AU>Leys D, Deplanque D, Mounier-Vehier C, Mackowiak-Cordoliani M-A, Lucas C, Bordet R</AU>
<TI>Stroke prevention: management of modifiable risk factors</TI>
<SO>Journal of Neurology</SO>
<YR>2002</YR>
<VL>249</VL>
<PG>507-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindenstrom-1993" NAME="Lindenstrom 1993" TYPE="JOURNAL_ARTICLE">
<AU>Lindenstrom E, Boysen G, Nyboe J</AU>
<TI>Lifestyle factors and the risk of cerebrovascular disease in women: the Copenhagen City Stroke Study</TI>
<SO>Stroke</SO>
<YR>1993</YR>
<VL>24</VL>
<PG>1468-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lissner-1991" NAME="Lissner 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lissner L, Odell PM, D'Agostino RB, Stokes J 3rd, Kreger BE, Belanger AJ, et al</AU>
<TI>Variability of body weight and health outcomes in the Framingham population</TI>
<SO>New England of Journal Medicine</SO>
<VL>324</VL>
<PG>1839-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Milionis-2003" NAME="Milionis 2003" TYPE="JOURNAL_ARTICLE">
<AU>Milionis HJ, Goudevenos J, Seferiadis K, Elisaf MS</AU>
<TI>Associations between body mass index and risks in elderly patients with a first-ever acute ischemic stroke [letter]</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<PG>980</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nat-Task-Force-1994" NAME="Nat Task Force 1994" TYPE="JOURNAL_ARTICLE">
<AU>National Task Force on the Prevention and Treatment of Obesity (Nat Task Force)</AU>
<TI>Weight cycling</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>272</VL>
<PG>1196-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nj_x00f8_lstad-1996" NAME="Njølstad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Njølstad I, Arnesen E, Lund-Larsen PG</AU>
<TI>Body height, cardiovascular risk factors, and risk of stroke in middle-aged men and women: a 14-year follow-up of the Finmark Study</TI>
<SO>Circulation</SO>
<YR>1996</YR>
<VL>94</VL>
<PG>2877-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohlson-1985" NAME="Ohlson 1985" TYPE="JOURNAL_ARTICLE">
<AU>Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, et al</AU>
<TI>The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913</TI>
<SO>Diabetes</SO>
<YR>1985</YR>
<VL>34</VL>
<PG>1055-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oppenheimer-1992" NAME="Oppenheimer 1992" TYPE="JOURNAL_ARTICLE">
<AU>Oppenheimer S, Hachinski V</AU>
<TI>Complications of acute stroke</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>339</VL>
<PG>721-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rexrode-1997" NAME="Rexrode 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW et al</AU>
<TI>A prospective study of body mass index, weight change, and risk of stroke in women</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>277</VL>
<PG>1539 -45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sacco-1997" NAME="Sacco 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM et al</AU>
<TI>American Heart Association Prevention Conference IV: prevention and rehabilitation of stroke: risk factors</TI>
<SO>Stroke</SO>
<YR>1997</YR>
<VL>28</VL>
<PG>1507-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Song-2004" NAME="Song 2004" TYPE="JOURNAL_ARTICLE">
<AU>Song YM, Sung J, Davey Smith G, Ebrahim S</AU>
<TI>Body mass index and ischemic and hemorrhagic stroke: a prospective study in Korean men</TI>
<SO>Stroke</SO>
<YR>2004</YR>
<VL>35</VL>
<PG>831- 6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" NAME="Sterne 2001" TYPE="BOOK_SECTION">
<AU>Sterne JAC, Egger M, Davey Smith G</AU>
<TI>Investigating and dealing with publication and other biases</TI>
<SO>Systematic Reviews in Health Care; Meta-analysis in Context</SO>
<YR>2001</YR>
<PG>189-208</PG>
<ED>EggerM, Davey SmithG, AltmanDG editor(s)</ED>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stokes-1985" NAME="Stokes 1985" TYPE="BOOK_SECTION">
<AU>Stokes III J, Garrison RJ, Kannel WB</AU>
<TI>The independent contributions of various indices of obesity to the 22-year incidence of coronary heart disease: The Framingham Heart Study</TI>
<SO>Metabolic Complications of Human Obesities</SO>
<YR>1985</YR>
<ED>Vague J, Björntorp P, Guy-Grand B, Rebuffe-Scrive M, Vague</ED>
<PB>Elsevier Science Publishers</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stokes-1987" NAME="Stokes 1987" TYPE="JOURNAL_ARTICLE">
<AU>Stokes J III, Kannel WB, Wolf PA, Cupples LA, D'Agostino RB</AU>
<TI>The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study</TI>
<SO>Circulation</SO>
<YR>1987</YR>
<VL>75 Suppl V</VL>
<PG>V65-V73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suk-2003" NAME="Suk 2003" TYPE="JOURNAL_ARTICLE">
<AU>Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, et al</AU>
<TI>Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study</TI>
<SO>Stroke</SO>
<YR>2003</YR>
<VL>34</VL>
<PG>1586-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tang-2000" NAME="Tang 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tang JL, Liu JLY</AU>
<TI>Misleading funnel plot for detection of bias in meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2000</YR>
<VL>53</VL>
<PG>477-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornton-2000" NAME="Thornton 2000" TYPE="JOURNAL_ARTICLE">
<AU>Thornton A, Lee P</AU>
<TI>Publication bias in meta-analysis: its causes and consequences</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2000</YR>
<VL>53</VL>
<PG>207-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2000" MODIFIED="2008-11-05 11:51:20 +0100" MODIFIED_BY="Gudrun Paletta" NAME="WHO 2000" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Obesity: preventing and managing the global epidemic</TI>
<SO>Report of a WHO consultation. World Health Organization Technical Report Series; 2000. Report No.: 894 i-xii, 1-253</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2004" NAME="WHO 2004" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>The Atlas of Heart Disease and Stroke</TI>
<SO>http://www.who.int/cardiovascular_diseases/resources/atlas/en/</SO>
<YR>(accessed 2004)</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-05 11:51:47 +0100" MODIFIED_BY="Gudrun Paletta"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>QUOROM (quality of reporting of meta-analyses) flow chart of study selection</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-21 14:08:08 +0200" MODIFIED_BY="Gudrun Paletta">
<APPENDIX ID="APP-01" MODIFIED="2008-10-04 17:32:03 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-04 17:31:40 +0200" MODIFIED_BY="[Empty name]">Search strategy for randomised or controlled clinical trials</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-04 17:32:03 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>Unless otherwise stated, search terms are free text terms; MesH = Medical subject heading (Medline medical index term); exp = exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) = substitutes one or no character; tw = text word; pt = publication type; sh = MeSH; adj = adjacent.<BR/>
<BR/>FIRST SEARCH STRATEGY<BR/>
<BR/>[1] search terms for stroke:<BR/>
<BR/>1) exp carotid artery thrombosis/<BR/>(2) exp cerebrovascular accident/<BR/>(3) exp Ischemic attack, transient/<BR/>(4) exp cerebral infarction/<BR/>(5) exp intracranial aneurysm/<BR/>(6) exp "Intracranial Embolism and THrombosis"/<BR/>(7) exp cerebral hemorrhage/ or exp basal ganglia hemorrhage/ or exp putaminal hemorrhage/ or exp intracranial hemorrhage, hypertensive/<BR/>(8) exp subarachnoid hemorrhage/<BR/>(9) (stroke$ or apoplex$ or post-stroke or poststroke).tw.<BR/>(10) lateral medullary syndrom$.tw.<BR/>(11) or/1-10<BR/>(12) (cereb$ or brain$).tw.<BR/>(13) exp Brain/<BR/>(14) 12 or 13<BR/>(15) exp Thrombosis/<BR/>(16) exp Embolism/<BR/>(17) exp Hemorrhage/<BR/>(18) (infarct$ or ischemi$ or ischaemi$ or thrombo$ or embol$ or haemorrhag$ or hemorrhag$ or bleeding).tw.<BR/>(19) or/15-18<BR/>(20) 14 and 19<BR/>(21) 11 or 20<BR/>
<BR/>[2] search terms for obesity or overweight:<BR/>
<BR/>(22) exp Obesity/<BR/>(23) exp Weight Loss/<BR/>(24) exp weight gain/<BR/>(25) exp body mass index/<BR/>(26) (weight adj2 (cyc$ or reduc$ or los$ or decreas$)).tw.<BR/>(27) over?weight$.tw.<BR/>(28) fat overload syndrom$.tw.<BR/>(29) (over?eat or over?feed).tw.<BR/>(30) (adipos$ or obes$).tw.<BR/>(31) body mass ind$.tw.<BR/>(32) or/22-31<BR/>
<BR/>[3] stroke and (obesity or overweight):<BR/>
<BR/>(33) 21 and 32<BR/>
<BR/>[4] search terms for randomised controlled clinical trials (RCT) or controlled clinical trials (CCT):<BR/>
<BR/>(34) randomized controlled trial.pt.<BR/>(35) controlled clinical trial.pt.<BR/>(36) randomized controlled trials.sh.<BR/>(37) random allocation.sh.<BR/>(38) double-blind method.sh.<BR/>(39) single-blind method.sh.<BR/>(40) or/34-39<BR/>(41) limit 40 to animal<BR/>(42) limit 40 to human<BR/>(43) 41 not 42<BR/>(44) 40 not 43<BR/>(45) clinical trial.pt.<BR/>(46) exp clinical trials/<BR/>(47) (clinic$ adj25 trial$).tw.<BR/>(48) ((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw.<BR/>(49) placebos.sh.<BR/>(50) placebo$.tw.<BR/>(51) random$.tw.<BR/>(52) research design.sh.<BR/>(53) (latin adj square).tw.<BR/>(54) or/45-53<BR/>(55) limit 54 to animal<BR/>(56) limit 54 to human<BR/>(57) 55 not 56<BR/>(58) 54 not 57<BR/>(59) comparative study.sh.<BR/>(60) exp evaluation studies/<BR/>(61) follow-up studies.sh.<BR/>(62) prospective studies.sh.<BR/>(63) (control$ or prospectiv$ or volunteer$).tw.<BR/>(64) cross-over studies.sh.<BR/>(65) or/59-64<BR/>(66) limit 65 to animal<BR/>(67) limit 65 to human<BR/>(68) 66 not 67<BR/>(69) 65 not 68<BR/>(70) 44 or 58 or 69<BR/>
<BR/>[5] stroke and (obesity or overweight) and (RCT or CCT):<BR/>
<BR/>(71) 33 and 70<BR/>
<BR/>
<BR/>SECOND SEARCH STRATEGY<BR/>
<BR/>[1] search terms for obesity or overweight:<BR/>
<BR/>(1) exp Obesity/<BR/>(2) exp body mass index/<BR/>(3) body mass ind$.tw.<BR/>(4) (adipos$ or obes$).tw.<BR/>(5) (over?eat or over?feed).tw.<BR/>(6) over?weight$.tw.<BR/>(7) exp Overweight/<BR/>(8) or/1-7<BR/>
<BR/>[2] search term for weight-loss interventions:<BR/>
<BR/>(9) exp Weight Loss/<BR/>(10) (weight adj6 (cyc$ or reduc$ or los$ or decreas$)).tw.<BR/>(11) exp Exercise/<BR/>(12) exp Diet/<BR/>(13) exp Drug Therapy/<BR/>(14) exercis$.tw.<BR/>(15) diet$.tw.<BR/>(16) surger$.tw.<BR/>(17) exp surgery/<BR/>(18) ((drug$ or agent$) adj6 (therap$ or treatment$ combination$)).tw.<BR/>(19) exp acupuncture therapy/<BR/>(20) exp psychotherapy/<BR/>(21) exp life style/<BR/>(22) ((pharmacological or pharmaceutical) adj6 (therap$ or treatment$ or drug$ or agent$)).tw.<BR/>(23) leisure activit$.tw.<BR/>(24) counselling.tw.<BR/>(25) (psychological adj6 (therap$ or treatment$ or advic$ or counsel$)).tw.<BR/>(26) or/9-25<BR/>
<BR/>[3] (Obesity or overweight) and weight-loss interventions:<BR/>
<BR/>(27) 8 and 26<BR/>
<BR/>[4] search terms for stroke - see FIRST SEARCH STRATEGY above<BR/>
<BR/>[5] (Obesity or overweight) and weight-loss interventions and stroke:<BR/>
<BR/>(49) 27 and 48<BR/>
<BR/>[6] RCT and CCT - see FIRST SEARCH STRATEGY above<BR/>
<BR/>[7] (Obesity or overweight) and weight-loss interventions and stroke and (RCT or CCT):<BR/>
<BR/>(87) 49 and 86<BR/>
<BR/>
<BR/>THIRD SEARCH STRATEGY<BR/>
<BR/>[1] search terms for obesity or overweight - see SECOND SEARCH STRATEGY above<BR/>
<BR/>[2] search terms for stroke:<BR/>
<BR/>(9) exp Cerebrovascular Accident/<BR/>(10) exp Carotid Artery Thrombosis/<BR/>(11) exp Ischemic Attack, Transient/<BR/>(12) exp Cerebral Infarction/<BR/>(13) exp Intracranial Aneurysm/<BR/>(14) exp "Intracranial Embolism and Thrombosis"/<BR/>(15) exp cerebral hemorrhage/ or exp basal ganglia hemorrhage/ or exp putaminal hemorrhage/ or exp intracranial hemorrhage, hypertensive/<BR/>(16) exp Subarachnoid Hemorrhage/<BR/>(17) exp Cardiovascular diseases/<BR/>(18) (stroke$ or apoplex$ or post?stroke).tw.<BR/>(19) lateral medullary syndrom$.tw.<BR/>(20) cardiovascular diseas$.tw.<BR/>(21) vascular diseas$.tw.<BR/>(22) isch?emic event$.tw.<BR/>(23) or/9-22<BR/>(24) (cereb$ or brain$).tw.<BR/>(25) exp brain/<BR/>(26) 24 or 25<BR/>(27) exp Thrombosis/<BR/>(28) exp Embolism/<BR/>(29) exp Hemorrhage/<BR/>(30) (infarct$ or isch?emi$ or thrombo$ or embol$ or h?emorrag$ or bleeding$).tw.<BR/>(31) or/27-30<BR/>(32) 26 and 31<BR/>(33) 23 or 32<BR/>
<BR/>
<BR/>[3] search terms for RCT:<BR/>
<BR/>(34) randomized controlled trial.pt.<BR/>(35) controlled clinical trial.pt.<BR/>(36) randomized controlled trials.sh.<BR/>(37) random allocation.sh.<BR/>(38) double-blind method.sh.<BR/>(39) single-blind method.sh.<BR/>(40) or/34-39<BR/>(41) limit 40 to animal<BR/>(42) limit 40 to human<BR/>(43) 41 not 42<BR/>(44) 40 not 43<BR/>
<BR/>[4] (Obesity or overweight) and stroke and RCT:<BR/>
<BR/>(45) 8 and 33 and 44<BR/>
<BR/>FOURTH SEARCH STRATEGY<BR/>
<BR/>[1] search terms for obesity or overweight - see SECOND SEARCH STRATEGY above<BR/>
<BR/>[2] search terms for weight-loss Interventions:<BR/>
<BR/>(9) exp Weight Loss/<BR/>(10) (exercis$ or physic$ activ$ or exert$ or physic$ fit$ or sports).tw.<BR/>(11) (weight adj6 (cyc$ or reduc$ or los$ or decreas$)).tw.<BR/>(12) (weight lift$ or strength train$ or resistance train$ or circuit weight train$).tw.<BR/>(13) exp exertion/<BR/>(14) exp "Physical Education and Training"/<BR/>(15) exp Physical Fitness/<BR/>(16) exp Sports/<BR/>
<BR/>(17) or/9-16<BR/>
<BR/>(18) exp Diet/<BR/>(19) exp Diet Therapy/<BR/>(20) diet$.tw.<BR/>(21) ad lib.tw.<BR/>
<BR/>(22) or/18-21<BR/>
<BR/>(23) exp Bariatric Surgery/<BR/>(24) exp Gastric Balloon/<BR/>(25) (gastroplasty or gastric band$ or gastric bypass or lap band or roux$ or gastro?gastrostomy or restrictive surgery or malabsorptive surgery or bariatric surgery or stomach bubble).tw.<BR/>(26) (gastric balloon$ or gastric bubble$ or stomach bubble).tw.<BR/>(27) jejuno?ileal bypass.tw.<BR/>
<BR/>(28) or/23-27<BR/>
<BR/>(29) exp Anti-Obesity Agents/<BR/>(30) exp appetite depressants/ or exp diethylpropion/ or exp phenmetrazine/ or exp phentermine/ or exp phenylpropanolamine/<BR/>(31) exp diethylpropion/ or exp phenmetrazine/ or exp phentermine/ or exp phenylpropanolamine/<BR/>(32) exp Mazindol/<BR/>(33) exp amphetamines/ or exp amphetamine/<BR/>(34) (appetite adj2 (reduc$ or inhibitor$ or depressant$ or suppressant$)).tw.<BR/>(35) (anorectic adj2 (agent$ or drug$ or compound$ or treatment$)).tw.<BR/>(36) (anti-obesity adj2 (agent$ or drug$)).tw.<BR/>(37) ((pharmacological or pharmaceutical) adj6 (therap$ or treatment$ or drug$ or agent$)).tw.<BR/>(38) (mazindol$ or benzocain$ or phentermin$ or phenmetrazin$ or phendimetrazin$ or fenfluramin$ or dexfenfluramin$ or diethylpropion$ or diethyl propion$ or benzphetamin$).tw.<BR/>(39) ((drug$ or agent$) adj2 (therap$ or treatment$ combination$)).tw.<BR/>
<BR/>(40) or/29-39<BR/>
<BR/>(41) exp acupuncture therapy/<BR/>(42) exp psychotherapy/<BR/>(43) exp life style/<BR/>(44) (behavio?r adj2 (therap$ or modific$)).tw.<BR/>(45) (cognitiv$ adj2 therap$).tw.<BR/>(46) (psychological adj6 (therap$ or treatment$ or advic$ or counsel$)).tw.<BR/>(47) ((pharmacological or pharmaceutical) adj6 (therap$ or treatment$ or drug$ or agent$)).tw.<BR/>(48) leisure activit$.tw.<BR/>
<BR/>(49) or/41-48<BR/>
<BR/>(50) 17 or 22 or 28 or 40 or 49<BR/>
<BR/>[3] search terms for stroke - see FIRST SEARCH STRATEGY above<BR/>
<BR/>[4] search terms for RCT or CCT - see FIRST SEARCH STRATEGY above<BR/>
<BR/>[5] search terms for cardiovascular disease:<BR/>
<BR/>(109) (cardiovascular adj2 disorder$).tw.<BR/>(110) (cardiovascular adj2 diseas$).tw.<BR/>(111) exp Cardiovascular Diseases/<BR/>
<BR/>[6] stroke or cardiovascular disease<BR/>
<BR/>[7] (stroke or cardiovascular disease) and (obesity or overweight) and RCT<BR/>
<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-10-04 17:32:34 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-10-04 17:32:15 +0200" MODIFIED_BY="[Empty name]">Search strategy for observational studies (prospective cohort studies)</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-04 17:32:34 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>Unless otherwise stated, search terms are free text terms; MesH = Medical subject heading (Medline medical index term); exp = exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) = substitutes one or no character; tw = text word; pt = publication type; sh = MeSH; adj = adjacent.<BR/>
<BR/>
<BR/>(1) exp Obesity/<BR/>(2) exp Weight Gain/<BR/>(3) exp Weight Loss/<BR/>(4) exp body mass index/<BR/>(5) exp Skinfold thickness/<BR/>(6) exp Waist-hip ratio/<BR/>(7) exp Abdominal fat/<BR/>(8) Quetelet inde$.tw.<BR/>
<BR/>(9) 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8<BR/>
<BR/>(10) *MORTALITY/<BR/>(11) *MORBIDITY/<BR/>(12) *EPIDEMIOLOGY/<BR/>(13) *PREVALENCE/<BR/>(14) *Primary Prevention/<BR/>(15) *Risk Factors/<BR/>(16) ((risk or mortality or morbidity or longevity or cohort or life expectancy or illness or incidence or predictor$ or death$ or disease$ or health outcome$) and (body size or BMI or body mass inde$ or overweight or over weight or obes$ or adipos$ or fat or hip circumference or waist)).ti.<BR/>
<BR/>(17) 10 or 11 or 12 or 13 or 14 or 15 or 16<BR/>(18) 9 and 17</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>